Resilience
Blue Ash, US Β· 12 known investors
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Also known as National Resilience Β· National Resilience, Inc. Β· Resilience Government Services (subsidiary)
Founders & leadership
Board
Investors Β· 12
Also in the syndicate Β· 1
Company profile
researched Aug 2026Resilience (also referred to as National Resilience, Inc.) is a technology-focused biomanufacturing contract development and manufacturing organization (CDMO) that develops and manufactures complex medicines, including biologics, vaccines, nucleic acid products, and cell and gene therapies, as well as finished drug product. Its service scope spans large-molecule biologics development and manufacturing, cell therapy development and manufacturing, aseptic drug product manufacturing (fill/finish), and device assembly, packaging and logistics, positioned as end-to-end drug substance and drug product solutions from concept through commercialization.
The company describes its purpose as broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption, operating a network of high-tech manufacturing sites intended to make medicines quickly, safely, sustainably and at scale. Branded offerings listed on its website include Sprout Solutions, Auto-T, DAR-T, Idea to Clinic and Build Your Resilience. A subsidiary, Resilience Government Services, contracts with U.S. government agencies on domestic production of key starting materials and active pharmaceutical ingredients for essential medicines.
Published company activity includes cell therapy manufacturing work (for example a 3-day short-cycle CAR-T manufacturing process whitepaper and expedited cell therapy QC capabilities), viral vector development and manufacturing, and process and analytical development. Reported inspection and assessment outcomes include USFDA cGMP, USFDA pre-approval inspection, USFDA pre-filled syringe and vial approval, Health Canada, and an EMA virtual inspection.
Founding story
Founded in 2020, during the COVID-19 pandemic, by Robert Nelsen, co-founder and managing director of ARCH Venture Partners, with 8VC also described as a co-founder participant. The stated founding rationale was the fragility of biopharmaceutical supply chains exposed by the pandemic and rising demand for complex medicines, motivating creation of a resilient domestic manufacturing network.
Business model
Contract development and manufacturing services sold to biopharmaceutical companies, covering process and analytical development, drug substance manufacturing, aseptic fill/finish, and device assembly, packaging and logistics. The company also states it pursues partnership models with aligned incentives rather than only standard contract structures, and runs a government-services subsidiary funded through federal awards.
Fee-based services under development and manufacturing agreements with biopharmaceutical partners, supplemented by government funding awards to its Resilience Government Services subsidiary.
Traction
The company states delivery of more than 100 million vials and pre-filled syringes per year and a 100% pass rate for third-party and EU Annex 1 assessments, alongside successful USFDA, Health Canada and EMA inspections. Third-party data lists employees at 10,000+ and cumulative funding of about $1.0B across six rounds. Publicly announced customer engagements include CARGO Therapeutics' allogeneic CAR-T program and Parvus Therapeutics' PVT401 for IBD.
Latest developments
In July 2026 Resilience and Lilly announced a combined $750 million investment expanding Resilience's advanced manufacturing operations in the Cincinnati region. In June 2026 the company announced relocation of its West Coast headquarters to Ohio and expansion of sterile manufacturing capabilities. In late 2025 it announced long-term financing of up to $825 million to accelerate its CDMO strategy.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned as a North America-based CDMO with regulatory experience serving customers in the EU, Asia, the Middle East and North America; described in third-party coverage as a technology-focused biomanufacturing company scaled through acquisitions of manufacturing and development facilities and backed by ARCH Venture Partners and 8VC. Sources note recognition on BioSpace's 2025 Best Places to Work list.
Sources cite next-generation manufacturing technologies and non-traditional, incentive-aligned partnership models; flexible facilities scaled for small and mid-sized biotechs; multi-modality coverage across biologics, cell and gene therapy and sterile drug product; and stated quality performance including a 100% pass rate on third-party and EU Annex 1 assessments.
Technology
Advanced biomanufacturing platforms spanning large-molecule biologics, cell therapy (including short-cycle CAR-T manufacturing and the DAR-T and Auto-T offerings), viral vector manufacturing, and aseptic drug product operations. The company also cites integrated/cloud data systems and AI-driven platforms supporting clinical development and manufacturing, rapid multi-omics cell therapy characterization, and QC turnaround of sample to report in 48 hours.
Go-to-market
Direct enterprise sales and partnership announcements with drug developers, supported by webinars, whitepapers, scientific presentations and conference/event presence covering fill/finish capacity, drug substance capacity and cell therapy manufacturing. Government business is pursued through a dedicated subsidiary that bids for federal preparedness and supply-chain funding.
Biopharmaceutical and biotech developers of complex medicines, from small and mid-sized innovators to large companies, plus U.S. government agencies via Resilience Government Services. Named partners include CARGO Therapeutics, Parvus Therapeutics and Eli Lilly.
Geography
North America-based, with facilities across the continental United States and Canada. Website-listed sites include Blue Ash, Ohio (headquarters), Cincinnati, Philadelphia and Toronto, with additional content referencing Boston, Massachusetts process/analytical development and manufacturing and an Alachua, Florida campus. Regulatory coverage extends to customers in the EU, Asia, the Middle East and North America.
History
After its 2020 founding, the company scaled rapidly through acquisitions of manufacturing and development facilities across North America and upgrades to digital systems, quality and capacity at those sites. Recent milestones include a $17.5 million ASPR/IBMSC award to its Resilience Government Services subsidiary (announced October 2024), the appointment of Susan Billings as Chief Commercial Officer (September 2024) and William S. Marth as Chief Executive Officer (December 2024), partnership announcements with Parvus Therapeutics and CARGO Therapeutics in January 2025, an expansion partnership with JobsOhio in Blue Ash (March 2025), long-term financing of up to $825 million announced in late 2025, relocation of its West Coast headquarters to Ohio with expanded sterile manufacturing (June 2026), and a $750 million joint investment with Lilly in U.S. manufacturing (July 2026).
Risks & controversies
Public sources reviewed do not describe litigation, regulatory actions or controversies. Data on funding structure is inconsistent across sources: a third-party aggregator lists round labels, amounts and investor names (including consumer/fintech-style investors) that conflict with the company's own disclosures of ARCH Venture Partners and 8VC backing, so those aggregator round details should be treated as low confidence.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Competitors Β· 1
by search overlap
Companies competing with Resilience for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline Β· 11
launches, deals, and filingsJoint investment by Resilience and Lilly expanding Resilience's advanced manufacturing operations in the Cincinnati region.
$750M source β
$825M source β
Funding supports domestic production of key starting materials and active pharmaceutical ingredients for essential medicines.
$17.5M source β
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
Lakestar Raises $300M Resilience Fund Itectonicdefense.com Β· Jul 2026
Resilience projects need funding. Green banks could help them reach new investors, one researcher says. | Smart Cities Divesmartcitiesdive.com Β· Jul 2026βΈResearch sources Β· 8
primary sources listed
- Resilienceresilience.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Resilience do?
- Biomanufacturing CDMO producing biologics, cell therapies and sterile drug products across North American facilities.
- Who are Resilience's investors?
- Resilience's investors include 8VC, ARCH Venture Partners, Catalio Capital Management, LP, GV (Google Ventures), Koch Disruptive Technologies, Lux Capital, Magnetic Ventures, New Enterprise Associates (NEA) and 3 more.
- Where is Resilience headquartered?
- Resilience is headquartered in Blue Ash, US.